NanoSyrinx Ltd
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Multiple Therapeutics
NanoSyrinx is a discovery-stage synthetic biology company specialising in the intracellular delivery of protein therapeutics using our nano-scale, cell-specific delivery technology - the Nanosyringe. We can package a wide range of payloads, from short peptides to large enzymes, into Nanosyringes then deliver these into target cells with antibody-equivalent specificity. This allows us to tackle intracellular targets which are challenging to drug using other approaches.
NanoSyrinx has raised >$20M to date and is backed by a consortium of top tier investors, including M Ventures, Eli Lilly, BGF and Octopus Ventures.
Company HQ City:
Coventry
Company HQ State:
England
Company HQ Country:
United Kingdom
Year Founded:
2020
Lead Product in Development:
Undisclosed
CEO
Thomas J Farrell
Development Phase of Lead Product
Discovery
When you expect your next catalyst update?
November 2026
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}